NEW YORK–(EMWPresswire)–IRX Therapeutics, a privately-held company dedicated to the discovery
and development of proprietary therapies for the treatment of cancer
and viral diseases, today announced that a symposium on findings from
its Phase 2 clinical trial of IRX-2 will be held on July 22, 2008 at
6:30 am (PDT) during the 7th International
Conference on Head and Neck Cancer at the San Francisco Marriot Hotel.
The American Head and Neck Society’s
International Conference on Head and Neck Cancer has been the world’s
pre-eminent meeting for head and neck cancer since its inception in
1984. Approximately 1,600 surgeons, oncologists, scientists and allied
health professionals are expected to attend.
The symposium, chaired by Dr. Gregory T. Wolf, current President of the
American Head and Neck Society, titled, “New
Paradigm for the Treatment for Head and Neck Cancer”
will include three presentations:
Arlene A. Forastiere, M.D., will present “Overview
of Current Therapies for Head and Neck Cancer.”
Dr. Forastiere is Professor of Oncology, Otolaryngology, Head and Neck
Surgery and Radiation Oncology at The Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins University.
Theresa L. Whiteside, Ph.D. will present “Overcoming
Immunosuppressive Effects in Head and Neck Cancer.”
Dr. Whiteside is Professor of Pathology, Immunology and Otolaryngology
and is Director of the Immunologic Monitoring and Cellular Products
Laboratory at the University of Pittsburgh School of Medicine.
Gregory T. Wolf, M.D., F.A.C.S., the Principal Investigator for the
Phase 2 trial of IRX-2, will present “IRX-2:
Promising New Immunotherapy for Head and Neck Cancer.”
Dr. Wolf is the Professor and Chair, Department of Otolaryngology and
Head and Neck Surgery at the University of Michigan as well as Director
of the University of Michigan Head and Neck Oncology SPORE Program.
Following the presentations there will be a panel discussion moderated
by Dr. Wolf on the role of immunotherapy in head and neck cancer.
IRX Therapeutics will also be sponsoring an exhibit booth at the
Conference highlighting the upcoming INSPIRE trial, a global Phase 3
clinical trial of IRX-2 in head and neck cancer.
About Head and Neck Cancer
Head and neck cancer is a deadly disease that often goes undiagnosed
until it is at an advanced stage. There are 500,000 new cases worldwide
each year, with about 45,000 new cases in the United States. Head and
neck cancer is associated with high rates of recurrence and mortality
and is understood to be highly immunosuppressive. The current standard
of care for newly diagnosed head and neck cancer is primarily curative
surgery followed by radiation therapy or, in some cases, chemoradiation.
For patients indicated for curative surgery, there is no approved
neoadjuvant therapy. The immunosuppressive nature of head and neck
cancer creates a potential role for immunotherapy as a neoadjuvant
intervention in the treatment of this disease.
About IRX Therapeutics
IRX Therapeutics is a privately-held immunotherapy company founded by
John W. Hadden, M.D., a pioneer in the field of Immunopharmacology. The
Company’s product platform seeks to restore
an effective cellular immune response for the treatment of advanced
cancers and viral diseases by correcting both dendritic cell and T-cell
defects. An effective immune response is essential for the eradication
of viruses and tumors.
The Company’s lead product, IRX-2
(citoplurikin), received Fast Track designation by the Food and Drug
Administration. Phase 1/2 and Phase 2 clinical trials in late-stage head
and neck cancer patients have been completed.
For more information on IRX Therapeutics, please visit the Company’s
website at http://www.irxtherapeutics.com.
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89